Camille Emprou

Camille Emprou

Auto-generated profile, based on publicly available information

Camille Emprou

Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble Alpes, Grenoble, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Oncogene
Verified
Journal Article
Closed access
PDF file
SAS Andò
S Andò
RMRocco Malivindi
Rocco Malivindi
SCStefania Catalano
Stefania Catalano
PRP Rizza
P Rizza
INES BARONEINES BARONE
INES BARONE
DMD Metzger
D Metzger

29 May 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CECamille Emprou
Camille Emprou
PQPauline Le Van Quyen
Pauline Le Van Quyen
JJJérémie Jégu
Jérémie Jégu
NPNathalie Prim
Nathalie Prim
NWNoëlle Weingertner
Noëlle Weingertner
MBMichèle Beau‐Faller
Michèle Beau‐Faller
Lymph node metastasis is an important prognosis factor in non‐small cell lung cancer (NSCLC) patients. The aim of this study was to investigate the role of epithelial to mesenchymal transition (EMT) in lymph node progression in the early stages of NSCLC. We studied a retrospective cohort of 160 consecutive surgically treated NSCLC patients with available frozen tumor samples for expression of EMT markers (CDH1, CTNNB1, CDH2, and VIMENTIN), inducers (TGFB1, c‐MET, and CAIX), and transcription factors (EMT‐TF: SNAI1, SNAI2, ZEB1, TWIST1, and TWIST2). Partial EMT was more frequent in N1‐2 (N+) vs N0 patients (P < .01). TGFB1 (P = .02) as well as SNAI2 (P < .01) and TWIST1 (P = .04) were the most differentially expressed genes in N+ tumors. In this group, ZEB1 was correlated with all EMT inducers and other EMT‐TFs were overexpressed depending on the inducers. CAIX was an independent prognostic factor for overall survival (IC 95% HR: 1.10‐5.14, P = .03). Partial EMT is involved in lymph node progression of NSCLC patients and depends on the TGFβ pathway. EMT‐TFs are differentially expressed depending on EMT inducers. CAIX might be a relevant prognostic marker in early stage NSCLC.

1 August 2021 in Lung Cancer
Verified
Journal Article
Closed access
AFAmal Fekkar
Amal Fekkar
CECamille Emprou
Camille Emprou
CLChristine Lefebvre
Christine Lefebvre
GFGilbert Ferretti
Gilbert Ferretti
OSOlivier Stephanov
Olivier Stephanov
SVSéverine Valmary-Degano
Séverine Valmary-Degano

4 January 2022 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
JBJustin Benet
Justin Benet
ATAnne-Claire Toffart
Anne-Claire Toffart
PBPierre-Yves Brichon
Pierre-Yves Brichon
TCThibaut Chollier
Thibaut Chollier
SRStéphane Ruckly
Stéphane Ruckly
MLMatteo Giaj Levra
Matteo Giaj Levra
Stage III NSCLC comprises a heterogeneous population. Different treatment strategies are available, including surgery, radiotherapy, and chemotherapy. The PACIFIC trial results represented a significant change and improvement in the therapeutic strategy for these patients. We aimed to compare the different treatment strategies employed in Stage III NSCLC patients within our institution. All Stage III NSCLC patients discussed during the weekly thoracic oncology multidisciplinary team meetings at the University hospital Grenoble Alpes (France) between January 2010 and January 2017 were included. Patients' overall survival (OS) according to treatment strategies along with their respective changes were compared. Overall, 476 patients were identified. Among patients initially scheduled to receive neoadjuvant chemotherapy followed by surgery (n = 60), only 37 (62%) actually underwent surgery. Median OS of the cohort was 21.3 months [IQR 25%-75%: 9.6-48.3]. Patients who received neoadjuvant chemotherapy followed by surgery displayed better survival than those treated by CT-RT: 53.2 months [IQR 25%-75%: 16.1-87.3] versus 23.9 [IQR 25%-75%, 13.3-48.1]. Survival was slightly superior for patients treated by upfront CT-RT than for those planned for neoadjuvant chemotherapy followed by surgery who eventually converted to CT-RT (concurrent or sequential): 23.9 months [IQR 25%-75%: 13.3-48.1] versus 20.4 [IQR 25%-75%:10.8-36], respectively. While patients who underwent neoadjuvant chemotherapy followed by surgery displayed a better survival than those treated using CT-RT, switch from surgery to CT-RT actually shortened survival. These results stress the relevance of the tumor board in deciding which is the best therapeutic strategy for Stage III disease patients.